By analyzing the transcriptome data of patients with HRD tumors, we found that downstream targets of the cGAS-STING pathway, such as CXCL10, were positively associated with HRD. The gene discussed is STING1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.